Immunology Landscape Globally Assessed & Projected by GBI Research in Topical Study Available at MarketPublishers.com12 Feb 2016 • by Natalie Aster
LONDON – Immune-mediated inflammatory diseases (IMIDs) are a very typical set of chronic illnesses affecting 5–7% of the populations in the Western world. Although being often disparate in some way, they are pathophysiologically related and are characterised by dysregulation of immune pathways and inappropriate immune responses. Generally, a group of medications such as disease-modifying anti-rheumatic drugs (DMARDs) are used in the first-line therapy for these diseases. These are supplemented in quite a few cases by shorter-term glucocorticoid therapy.
Nevertheless, as these treatments frequently fail to evoke an adequate long-term response, a big second-line treatment option has emerged in these markets, starting with the approval of Enbrel (etanercept) and Remicade (infliximab) in 1998. The segment mainly comprises premium systemic monoclonal antibodies (mAbs), which are commercially successful owing to their high cost and widespread use. Though the patents for many of these mAbs have already expired or are expected to expire in the offing, the market is forecast to gain steady momentum.
The market is expected to grow from USD 61.5 billion as of 2015 to reach the USD 74.2 billion mark in 2022, posting a CAGR of 2.71%. Currently, there are 1,838 immunology products in clinical development. Still, the late-stage product’s commercial performance will likely be moderate, with a number of leading products, comprising Remicade and Humira (adalimumab), poised to see the loss of patent protection in the long run. The dominant market players are projected to maintain their market leadership positions throughout the forecast period.
Topical study “Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth” created by GBI Research takes an in-depth look at the immunology market. The report reviews the clinical and commercial landscape as of today, examines the structure of the market across the key indications and highlights the major commercial assets and players; assesses the immunology pipeline and segments it by development stage, molecule type and target, with a clear breakdown across major indications; tracks the growth in patient epidemiology and immunology market revenues worldwide and across the top players and products; reviews the generic and premium products alongside assessing their role in the treatment of the different immunological disorders. The study identifies the factors that are propelling and hindering the market growth. Furthermore, granular multi-scenario market forecast is provided through to 2022.
Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth
Published: December, 2015
Price: US$ 4,995.00
More reports by the publisher can be found at GBI Research page.